| Experimental Information |
| |
| Enzymatic Activity |
| Molecule Id | EGIN0004382 |
| PMID | 22361272 |
| Assay Used | Solid-phase ELISA assay and antiproliferation assay |
| Experimently Validated | yes |
| EGFR (IC50) | 3030 ± 350 nM |
| HER2 (IC50) | 4640 ± 420 nM |
| HER4 (IC50) | - |
| Mutant L858R (IC50) | - |
| Mutant T790M (IC50) | - |
| Double Mutant (IC50) | - |
| Average ERBB2 and ERBB1 (IC50) | - |
| Inhibition EGFR (%) | - |
| Inhibitory Concentration | - |
| Inhibition HER2 (%) | - |
| Inhibitory Concentration | - |
| Ki (EGFR) | - |
| Ki (HER2) | - |
| Ki (HER4) | - |
| Kd (EGFR) | - |
| Kd (L858R) | - |
| Kd (T790M) | - |
| Kd (L858R/T790M) | - |
| Kd (Other mutation) | - |
| Note | The paper describes design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors |
| Extra | - |
| |
